Peptide Therapeutics Industry News In October 2025, Kazia Therapeutics partnered with QIMR Berghofer to develop NDL2, a first-in-class bicyclic peptide degrader targeting resistant PD-L1 forms
Losing weight can be a challenging journey, often fraught with frustration and setbacks
Moreover, you can get it without insurance through verified telehealth providers
Post-marketing surveillance data have not identified infertility as a recognized adverse effect, though such passive reporting systems have inherent limitations in detecting subtle reproductive impacts
While semaglutide GLP-1 helps curb appetite and promote weight loss, it is crucial to maintain a healthy lifestyle and adhere to the prescribed treatment plan to optimize its effects
Compared to bariatric surgery, semaglutide offers similar weight loss results for many people without surgical risks, recovery time, or permanent anatomical changes